- Home
- EVN vs LYEL Comparison
EVN vs LYEL Comparison
Compare EVN & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVN
- LYEL
- Stock Information
- Founded
- EVN 1998
- LYEL 2018
- Country
- EVN United States
- LYEL United States
- Employees
- EVN N/A
- LYEL N/A
- Industry
- EVN Investment Bankers/Brokers/Service
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- EVN Finance
- LYEL Health Care
- Exchange
- EVN Nasdaq
- LYEL Nasdaq
- Market Cap
- EVN 398.3M
- LYEL 203.9M
- IPO Year
- EVN N/A
- LYEL 2021
- Fundamental
- Price
- EVN $10.01
- LYEL $0.57
- Analyst Decision
- EVN
- LYEL Sell
- Analyst Count
- EVN 0
- LYEL 2
- Target Price
- EVN N/A
- LYEL $1.00
- AVG Volume (30 Days)
- EVN 101.2K
- LYEL 1.3M
- Earning Date
- EVN 01-01-0001
- LYEL 02-26-2025
- Dividend Yield
- EVN 4.78%
- LYEL N/A
- EPS Growth
- EVN N/A
- LYEL N/A
- EPS
- EVN 0.34
- LYEL N/A
- Revenue
- EVN N/A
- LYEL $63,000.00
- Revenue This Year
- EVN N/A
- LYEL N/A
- Revenue Next Year
- EVN N/A
- LYEL N/A
- P/E Ratio
- EVN $29.94
- LYEL N/A
- Revenue Growth
- EVN N/A
- LYEL N/A
- 52 Week Low
- EVN $8.64
- LYEL $0.55
- 52 Week High
- EVN $10.45
- LYEL $3.26
- Technical
- Relative Strength Index (RSI)
- EVN 39.71
- LYEL 31.22
- Support Level
- EVN $9.90
- LYEL $0.60
- Resistance Level
- EVN $10.23
- LYEL $0.72
- Average True Range (ATR)
- EVN 0.11
- LYEL 0.05
- MACD
- EVN 0.00
- LYEL 0.01
- Stochastic Oscillator
- EVN 33.33
- LYEL 12.13
About EVN Eaton Vance Municipal Income Trust
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.